SK Biopharmaceuticals Co., Ltd. (326030.KS)

KRW 103600.0

(-2.54%)

Operating Expenses Summary of SK Biopharmaceuticals Co., Ltd.

SK Biopharmaceuticals Co., Ltd.'s latest annual operating expenses in 2023 was 358.33 Billion KRW , up 1.89% from previous year.
SK Biopharmaceuticals Co., Ltd.'s latest quarterly operating expenses in 2024 Q2 was 96.05 Billion KRW , up 8.44% from previous quarter.
SK Biopharmaceuticals Co., Ltd. reported a annual operating expenses of 339.48 Billion KRW in annual operating expenses 2022, up 12.66% from previous year.
SK Biopharmaceuticals Co., Ltd. reported a annual operating expenses of 301.35 Billion KRW in annual operating expenses 2021, up 14.35% from previous year.
SK Biopharmaceuticals Co., Ltd. reported a quarterly operating expenses of 88.58 Billion KRW for 2024 Q1, down -6.44% from previous quarter.
SK Biopharmaceuticals Co., Ltd. reported a quarterly operating expenses of 79.5 Billion KRW for 2023 Q1, down -17.89% from previous quarter.

Annual Operating Expenses Chart of SK Biopharmaceuticals Co., Ltd. (2023 - 2011)

Historical Annual Operating Expenses of SK Biopharmaceuticals Co., Ltd. (2023 - 2011)

Year	Operating Expenses	Operating Expenses Growth
2023	358.33 Billion KRW	1.89%
2022	339.48 Billion KRW	12.66%
2021	301.35 Billion KRW	14.35%
2020	263.52 Billion KRW	30.07%
2019	202.59 Billion KRW	44.5%
2018	140.2 Billion KRW	38.07%
2017	101.54 Billion KRW	47.71%
2016	68.74 Billion KRW	5.49%
2015	65.16 Billion KRW	0.11%
2014	65.09 Billion KRW	8.11%
2013	60.21 Billion KRW	20.15%
2012	50.11 Billion KRW	63.39%
2011	30.67 Billion KRW	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	96.05 Billion KRW	8.44%
2024 Q1	88.58 Billion KRW	-6.44%
2023 Q1	79.5 Billion KRW	-17.89%
2023 Q3	-94.25 Billion KRW	-8.87%
2023 Q2	-86.57 Billion KRW	-208.9%
2023 FY	345.89 Billion KRW	1.89%
2023 Q4	94.67 Billion KRW	200.45%
2022 FY	339.48 Billion KRW	12.66%
2022 Q4	96.82 Billion KRW	14.12%
2022 Q3	84.84 Billion KRW	-0.83%
2022 Q2	85.55 Billion KRW	18.37%
2022 Q1	72.27 Billion KRW	-10.23%
2021 FY	301.35 Billion KRW	14.35%
2021 Q4	80.5 Billion KRW	12.33%
2021 Q2	86.96 Billion KRW	39.79%
2021 Q3	71.66 Billion KRW	-17.59%
2021 Q1	62.21 Billion KRW	-10.05%
2020 FY	263.52 Billion KRW	30.07%
2020 Q4	69.16 Billion KRW	3.8%
2020 Q2	59.09 Billion KRW	-13.92%
2020 Q1	68.64 Billion KRW	4.35%
2020 Q3	66.62 Billion KRW	12.75%
2019 Q4	65.78 Billion KRW	30.07%
2019 FY	202.59 Billion KRW	44.5%
2019 Q3	50.57 Billion KRW	12.78%
2019 Q2	44.84 Billion KRW	8.33%
2019 Q1	41.39 Billion KRW	0.0%
2018 FY	140.2 Billion KRW	38.07%
2017 FY	101.54 Billion KRW	47.71%
2016 FY	68.74 Billion KRW	5.49%
2015 FY	65.16 Billion KRW	0.11%
2014 FY	65.09 Billion KRW	8.11%
2013 FY	60.21 Billion KRW	20.15%
2012 FY	50.11 Billion KRW	63.39%
2011 FY	30.67 Billion KRW	0.0%

Peer Operating Expenses Comparison of SK Biopharmaceuticals Co., Ltd.

Name	Operating Expenses	Operating Expenses Difference
ORIENT BIO Inc.	10.23 Billion KRW	-3402.63%
Green Cross Holdings Corporation	620.02 Billion KRW	42.207%
Green Cross Holdings Corporation	424.43 Billion KRW	15.574%
Pharmicell Co., Ltd.	14 Billion KRW	-2458.743%
Green Cross Corporation	424.43 Billion KRW	15.574%
GeneOne Life Science, Inc.	40.6 Billion KRW	-782.398%
Celltrion, Inc.	359.46 Billion KRW	0.316%
Samsung Biologics Co.,Ltd.	638.51 Billion KRW	43.881%
SK bioscience Co.,Ltd.	154.23 Billion KRW	-132.335%
Prestige BioPharma Limited	63.47 Billion KRW	-464.55%